Internal Medicine, IMIBIC, University Hospital Reina Sofía, 14004, Córdoba, Spain.
Servicio de Cardiología, Hospital la Paz de Madrid, 28046, Madrid, Spain.
Future Cardiol. 2023 May;19(6):333-342. doi: 10.2217/fca-2023-0015. Epub 2023 Jun 29.
To address the projected clinical benefits of dapagliflozin among patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). A multicenter, prospective, cohort study of patients ≥50 years admitted with HF to Spanish internal medicine departments. The projected clinical benefits of dapagliflozin were calculated from the DELIVER trial. A total of 4049 patients were included; 3271 (80.8%) were eligible for dapagliflozin treatment, according to DELIVER criteria. Within 1 year after discharge, 22.2% were rehospitalized for HF and 21.6% died. Implementation of dapagliflozin would translate into an absolute risk reduction of 1.3% for mortality and 5.1% for HF readmission. HF patients with preserved or mildly reduced ejection fraction have a high risk of events. The use of dapagliflozin could substantially reduce the HF burden.
为了评估达格列净在射血分数轻度降低（HFmrEF）和射血分数保留（HFpEF）心力衰竭（HF）患者中的预期临床获益。一项多中心、前瞻性队列研究，纳入≥50 岁因 HF 入住西班牙内科病房的患者。根据 DELIVER 试验，计算达格列净的预期临床获益。共纳入 4049 例患者；根据 DELIVER 标准，3271 例（80.8%）符合达格列净治疗条件。出院后 1 年内，22.2%因 HF 再次住院，21.6%死亡。实施达格列净治疗可使死亡率的绝对风险降低 1.3%，HF 再入院率降低 5.1%。射血分数保留或轻度降低的 HF 患者发生事件的风险较高。使用达格列净可显著降低 HF 负担。
